Epithalon
Also known as Epitalon, Epithalone, Ala-Glu-Asp-Gly, AEDG peptide, Epithalamin analog
Epithalon is a four-amino-acid synthetic peptide from the Khavinson group designed to mimic epithalamin, a pineal gland extract. It is the best known longevity peptide, used for telomere support, sleep, and general anti-aging.
Reviewed by the amino101 editorial team. , first published .
Quick start
What people commonly do. Not a prescription.- Typical dose
- 5 to 10 mg
- How often
- once daily
- Where
- Subcutaneous, belly or thigh; intramuscular, intranasal, and oral are also used, with no human route comparison
- Timing
- evening or before bed, since it acts on melatonin rhythm; morning use is also common
- Effects timeline
- sleep changes and vivid dreams within the first week; anything else is not measurable at home
- Storage
- fridge 2 to 8 C once mixed, use within 4 weeks; lyophilized in fridge or freezer away from light
- Cycle length
- 10 to 20 days per course
- Break between
- 1 to 2 courses per year, so roughly 6 months between courses
Overview
Epithalon is the tetrapeptide Ala-Glu-Asp-Gly, created at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s and 1990s as a synthetic replacement for epithalamin, a bovine pineal extract the group had studied for decades. It is the flagship of the bioregulator family and the one with the largest body of published work, most of it from Vladimir Khavinson and collaborators including the oncologist Vladimir Anisimov.
The headline finding is that Epithalon increased telomerase activity and lengthened telomeres in cultured human fibroblasts, published in 2003. In mice, long-term treatment was reported to extend lifespan in some strains, reduce spontaneous tumor incidence in others, and normalize circadian melatonin rhythms. In aged rhesus monkeys it restored nighttime melatonin peaks and improved glucose and cortisol patterns. These are real published results, but nearly all originate from one network of researchers and independent replication of the telomere claim is lacking.
Human evidence is mostly for epithalamin, the extract, including a 12-year Russian follow-up of elderly patients who received periodic courses and showed lower mortality and better cardiovascular and immune markers than controls. Smaller studies used Epithalon itself for sleep, retinal disease, and immune markers in older adults. None were large or blinded to modern standards. The peptide is generally well tolerated, and its wide use in the community rests on this combination of intriguing animal data and thin human trials.
How it works
Epithalon is proposed to act on gene expression, most notably by inducing transcription of telomerase reverse transcriptase (TERT) in somatic cells, which lengthens telomeres in culture. Whether that happens meaningfully in a living adult is unproven. It also acts on the pineal gland, increasing nighttime melatonin synthesis and restoring circadian amplitude in aged animals, which likely explains the sleep effects people report. Other reported actions include antioxidant effects, modulation of interferon gamma and other immune genes, reduced expression of some oncogenes in mouse tissue, and normalization of gonadotropin rhythms. Khavinson's model has the peptide binding DNA directly and altering chromatin accessibility, a hypothesis that remains largely untested outside his group.
Where the research stands
Sleep and circadian rhythmModerate evidence
- Melatonin rhythm restoration. Aged rhesus monkeys and rodents regained nighttime melatonin peaks; this is the most consistent animal finding.
- Sleep quality in older adults. Small Russian studies reported better sleep; open-label and not independently replicated.
Telomeres and cellular agingEmerging
- Telomerase activation and telomere elongation. Cultured human fibroblasts only, from one 2003 study; never shown in a living adult.
- Lifespan and tumor incidence in mice. Rodent; modest lifespan extension and fewer spontaneous tumors in some strains, all from one research network.
Immune and endocrine markers in agingEmerging
- 12 year follow-up of elderly patients. Human open-label follow-up using the epithalamin extract, not the peptide, reported lower mortality than untreated controls.
- Immune markers in older adults. Small Russian pilot studies with the peptide reported improved immune indices.
Retinal diseaseWeak or mixed
- Retinitis pigmentosa. Small Russian reports, mostly with the extract, with no controlled trial.
- in vitroEpithalon induced telomerase activity and telomere elongation in cultured human somatic cells.
- rodentLong-term Epithalon treatment in female SHR mice reduced spontaneous tumor incidence and modestly extended lifespan in some cohorts.
- rodentEpithalon restored nighttime melatonin peaks and normalized cortisol and glucose rhythms in aged rhesus monkeys.
- human pilotA 12-year follow-up of elderly patients receiving periodic epithalamin extract reported lower mortality than untreated controls.
- human pilotSmall Russian studies with Epithalon in older adults reported improved sleep and immune markers.
Rodent and in vitro mean no human data for that finding. Human pilot means small, often uncontrolled. Human RCT means randomized and controlled. Clinical means an approved drug with regulatory data.
Levels over time
Modeled from the half-life. Illustrative, not measured.A half-life of 6 min against dosing every 24 h means each dose has cleared before the next. Nothing stacks; you start from zero every time, and the tissue effect is what carries over.
Plasma presence is fleeting, so the 10 to 20 day course design is about cumulative exposure, and the effects people report, like deeper sleep, build over the course rather than after a single dose.
Epithalon dosage and protocols
A course of 10 to 20 daily doses, repeated once or twice a year, mirrors the Russian elderly studies. No loading or taper. Some people run lower doses for longer, which has no data behind it.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard course | 5 mg | once daily for 20 days | Subcutaneous, evening |
| Shorter, higher course | 10 mg | once daily for 10 days | Subcutaneous, evening |
| Intramuscular alternative | 5 to 10 mg | once daily for 10 to 20 days | Intramuscular |
| Intranasal or oral | 5 to 10 mg | once daily for 10 to 20 days | Intranasal or oral, absorption unverified |
Evening dosing lines up with its melatonin effect and the vivid dreams people report. Food does not matter for injection. Commonly run in the same course as Pinealon or alongside DSIP at night.
Daily for 10 to 20 days per course. Some people use a lower dose for a longer period, but the 5 to 10 mg short course is the pattern most often cited.
Dose calculator
U-100 insulin syringeUnits are a volume on the syringe, not an amount of peptide. Concentration changes every time you change the water volume. The standalone calculator explains the math.
| Vial | Suggested water | Concentration | Low dose draw |
|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | 50 units |
| 20 mg | 2 mL | 10 mg/mL | 50 units |
| 50 mg | 3 mL | 16.667 mg/mL | 30 units |
How to reconstitute Epithalon
- 1
Wash your hands and wipe the work surface. Swab both vial stoppers with alcohol and let them dry.
- 2
Pick the water volume with the calculator above and write it on the vial. The concentration means nothing without it.
- 3
Draw the bacteriostatic water into a mixing syringe.
- 4
Insert at an angle and let the water run down the inside wall. Never squirt it straight onto the powder.
- 5
Swirl gently or leave it to dissolve. Do not shake.
- 6
Label with the date and water volume. Store in the fridge at 2 to 8 C and use within about 4 weeks.
- 7
Unmixed vials keep for months in the fridge and longer in the freezer, sealed and out of light.
- Full walkthrough with syringe reading and site rotation: reconstitution guide.
- ✓White, fluffy cake
Lyophilized powder should look like a small white puck or fluffy cake at the bottom of the vial. That is a proper freeze-dry.
- ✓Clear after mixing
Once dissolved the solution should be water-clear with nothing floating in it.
- !Slight clumping
Small clumps that dissolve with gentle swirling are fine. Shipping compacts powder.
- ✕Collapsed or melted
Powder stuck to the sides, glassy, or shrunken means it got hot in transit. Contact the vendor.
- ✕Cloudy or particles
Persistent cloudiness or visible particles after mixing means degraded or contaminated product. Do not use it.
- Week 1
Deeper sleep and vivid dreams are the most common reports; some mild daytime drowsiness.
- Week 2 to 3
Sleep rhythm feels steadier; nothing else is measurable at home.
- After the course
The sleep benefit fades over a few weeks; no rebound has been reported.
- Long term
Telomere or lifespan claims cannot be verified by the user, and no human study has measured them.
Interactions and stacking
Pinealoncompatible
Brain and pineal bioregulators are paired in the Khavinson protocols; no controlled data on the combination.
DSIPsynergistic
Both are used at night for sleep, Epithalon through melatonin rhythm and DSIP through its own pathway; combined data does not exist.
MOTS-ccompatible
Telomere and mitochondrial angles in one longevity stack; no overlap and no combined data.
NAD+compatible
Common longevity pairing with no interaction expected and no data either way.
Melatonin supplementscaution
Epithalon raises nighttime melatonin in animals, so adding melatonin on top can overshoot into grogginess.
Sedatives and sleep medicationscaution
Additive drowsiness is possible given the sleep effect; no formal interaction data.
Active cancer or cancer historyavoid
Telomerase activation is a theoretical concern even though mouse data showed fewer tumors; the human data is too thin to rule anything out.
Safety
- ▲Vivid dreams
- ▲Drowsiness or fatigue during the course
- ▲Injection site reactions
- ▲Occasional headache
- ▲No serious adverse effects reported in the small trials, which is limited reassurance
- ▲The telomere-lengthening result is a cell culture finding; no one has shown it happens in adult humans.
- ▲Telomerase activation is theoretically double-edged, since most cancers rely on it, though mouse data showed fewer tumors.
- ▲Human trials are small, mostly open-label, and largely of the extract rather than the peptide.
- ▲Vivid dreams and mild drowsiness are common; some report fatigue during a course.
- ▲Nearly all published work comes from one research network.
- ■Daytime fatigue that does not lift after the first week
- ■A new cancer diagnosis or a suspicious lesion appears during use
- ■An allergic reaction at the injection site or elsewhere
- ■Sleep gets worse instead of better
Community poll
Self-reported by visitors. Not clinical evidence.Epithalon: frequently asked
Does Epithalon actually lengthen telomeres?
In cultured human fibroblasts, yes, according to a 2003 study from the Khavinson group. In living people there is no direct evidence. The idea is plausible given the telomerase induction, but a cell dish is a long way from a human body and no one has measured telomere length before and after Epithalon courses in a controlled trial.
How much and how often?
The most commonly cited protocol is 5 to 10 mg daily by injection for 10 to 20 days, repeated once or twice a year. That mirrors the course structure used in the Russian elderly studies. Some people run lower daily doses for longer, which has no specific data behind it.
Is there a cancer risk from activating telomerase?
It is a fair concern in theory, since cancer cells depend on telomerase. The mouse lifespan studies actually found fewer spontaneous tumors with Epithalon, and no human signal has emerged, but the human data is too thin to rule anything out. Anyone with a cancer history should think carefully.
Does it help sleep?
Many users report deeper sleep and vivid dreams, consistent with the animal data showing restored melatonin rhythm. This is the most reproducible subjective effect. Evening dosing is common for that reason.
Oral, nasal, or injected?
Injection was used in the research and is the community standard. Oral and nasal products exist and short peptides may survive digestion better than long ones, but there is no human comparison of routes.
References
- Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 2003
- Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 2003
- Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuroendocrinology Letters, 2001
- Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters, 2003